Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells

Leland Metheny III1,2,*, Saada Eid3, Karen Lingas2, Jane Reese2, Howard Meyerson4, Alexander Tong2, Marcos de Lima1,2, and Alex Y Huang3,4

1Stem Cell Transplant Program, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, OH 44106, USA
2Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
3Division of Pediatric Hematology/Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine; Angie Fowler AYA Cancer Institute, University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH 44106, USA
4Department of Pathology, Case Western Reserve University School of Medicine; University Hospitals Case Medical Center, Cleveland, OH 44106, USA

Abstract

Human mesenchymal stromal cells (MSC) have been shown to support the growth and differentiation of hematopoietic stem cells (HSC). We hypothesized that intra-osseous (IO) co-transplantation of MSC and umbilical cord blood (UCB) may be effective in improving early HSC engraftment, as IO transplantation has been demonstrated to enhance UCB engraftment in NOD SCID-gamma (NSG) mice. Following non-lethal irradiation (300rads), 6 groups of NSG mice were studied: 1) intravenous (IV) UCB CD34+ cells, 2) IV UCB CD34+ cells and MSC, 3) IO UCB CD34+ cells, 4) IO UCB CD34+ cells and IO MSC, 5) IO UCB CD34+ cells and IV MSC, and 6) IV UCB CD34+ and IO MSC. Analysis of human-derived CD45+, CD3+, and CD19+ cells 6 weeks following transplant revealed the highest level of engraftment in the IO UCB plus IO MSC cohort. Bone marrow analysis of human CD13 and CD14 markers revealed no significant difference between cohorts. We observed that IO MSC and UCB co-transplantation led to superior engraftment of CD45+, CD3+, and CD19+ lineage cells in the bone marrow at 6 weeks as compared with the IV UCB cohort controls. Our data suggests that IO co-transplantation of MSC and UCB facilitates human HSC engraftment in NSG mice.
Keywords

- cord blood stem cell transplantation
- mesenchymal stromal cells
- hematopoietic stem cell transplantation

Introduction

Umbilical cord blood (UCB) is rich in hematopoietic stem cells (HSC) and it has been used as a graft source for both hematopoietic stem cell transplant (SCT) patients and murine models of transplant [1,2]. Usually, UCB is given after conditioning chemotherapy or radiation through intravenous (IV) infusion. However, due to delayed or sub-optimal engraftment in both mice and humans, other methods beyond IV infusion have been proposed. These include intra-osseous infusion, co-infusion of the UCB with mesenchymal stromal cells (MSC), or ex vivo expansion of UCB prior to infusion [3-5]. Here we report our data on intra-osseous co-infusion of UCB and MSC in a murine model of transplant.

It has been shown that a large percentage of HSCs, when introduced IV, do not reach the bone marrow niche [6,7]. Cui et al. demonstrated that when fluorescently labelled donor bone marrow cells are injected IV in an irradiated syngeneic mouse model, only 1-2% of donor HSCs reached the bone marrow [6]. In mouse models, direct IO injection of HSC improves overall engraftment, possibly by bypassing potential “trapping” sites in multiple organs including the lung, liver, spleen and kidney [8-10]. In an experiment performed by Castello et al. direct IO inoculation of UCB resulted in higher engraftment rates when compared to IV UCB injection 30 days post transplantation, as measured by the abundance of human myeloid cells, identified by CD45+ cells within the bone marrow [9].

The bone marrow microenvironment provides an important niche for the proliferation and differentiation of HSC [11-14]. Human MSC have been shown to support the growth and differentiation of HSC [15]. Bone marrow MSC support hematopoietic growth through a number of mechanisms including the production of IL-6, IL-11, leukemia inhibitory factor, stem cell factor and thrombopoietin [16,17]. MSC also aid in the homing and migration of HSC to the bone marrow [18]. Furthermore, the addition of MSC ex vivo to UCB cultures results in significant expansion of the hematopoietic stem (CD34+) cell pool. This method of ex vivo expansion has been used to increase the cell dosages of UCB grafts in patients undergoing SCT [12].

MSCs have also been co-infused with CD34-selected human UCB IV in a murine model of hematopoietic stem cell transplant [19]. In this model, mice transplanted with CD34 selected UCB and Stro-1+ MSCs exhibited significantly greater human hematopoietic engraftment in the bone marrow, spleen and blood (CD45%: 48, 35, and 14, respectively) when compared to mice transplanted with UCB alone (CD45%: 27, 15, and 4, respectively) at 12 weeks following transplantation. These data formed the basis for the approach of using a combination of MSC and UCB co-transplantation IV in clinical trials, which were found to be safe [20].
Carrancio et al. demonstrated that in a mouse transplantation model, co-infusion of human MSCs and human CD34+ UBC enhanced the engraftment of myeloid compartment when compared to controls [21]. Mice co-transplanted with MSC and UCB by either the IV or IO route had greater B-cell (CD19+) and myeloid (CD13+) chimerism at 3 weeks following transplantation. Furthermore, mice transplanted with IO UCB and IO MSC had the greatest rate of human engraftment (CD45+) in the injected femur. Based on the data above, we hypothesized that co-transplantation of MSC and UCB via direct IO route would further improve early human engraftment in a mouse transplantation model.

Methods

Mice

Non-Obese Diabetic- Severe Combined Immunodeficiency-IL2Rgammanull (NSG) mice were from breeding pairs originally purchased from Jackson Laboratories. NSG were bred in a pathogen-free unit and maintained in sterile cages.

Human MSCs

Human MSC (CD105+ CD73+ CD45− CD14−) were obtained from bone marrow donors using Percoll gradient isolation and culture-expanded to a homogeneous population under approved protocols in the National Center for Regenerative Medicine/Seidman Cancer Center Cellular Therapy Lab. MSCs were preserved in DMSO and when needed were thawed and re-suspended at the appropriate concentration per cohort.

CD34+ UCB cell isolation

Cord blood units were received from the Cleveland Cord Blood Center. Each unit was diluted 1:3 with Phosphate Buffered Saline (PBS) + 0.5% Human Serum Albumin (HSA) and layered onto Ficoll Paque PLUS to isolate the mononuclear cells by density gradient. After a cell count and washes, the mononuclear cells were labeled per protocol using the Miltenyi Biotec CD34 Microbead Kit. The CD34 cells were then isolated using an LS column in a magnet and washed three times with MACS buffer. The CD34 cells from both cord blood units were combined, counted, and re-suspended in PBS for injection into mice.

Murine transplantation

Female Nude Obese Diabetic Severe Combined Immunodeficiency (NSG) mice aged 8 to 12 weeks were purchased from Jackson Laboratory (Bar Harbor, ME). Prior to SCT, recipient mice were ear punched for individual identification. Mice received allogeneic SCT using CD34 selected human umbilical cord blood. NSG mice received 300 cGy TBI immediately prior to receiving 5 × 10^5 CD34+ selected cells from human umbilical cord blood with or without 1 × 10^6 human MSC.

Six groups of NSG mice were studied: 1) intravenous (IV) 5×10^5 UCB CD34+ cells, 2) IV 5×10^5 UCB CD34+ cells and 1 × 10^6 MSC, 3) IO 5 × 10^5 UCB CD34+ cells, 4) IO 5 × 10^5 UCB CD34+ cells and IO 1 × 10^6 MSC, 5) IO 5×10^5 UCB CD34+ cells and IV 1 × 10^6 MSC, and 6) IV 5×10^5 UCB CD34+ and IO 1 × 10^6 MSC. MSC dose was arbitrarily set at 2:1 with UCB CD34+ cell dose. IV injections: cells were administered via tail vein injection.
suspended in a total volume of 200 μl. IO injections: Mice were anesthetized using fluorine gas, the left leg was shaved, the hair removed and betadine was applied to the skin. Cells were administered via bilateral tibia IO injections suspended in a total volume of 40 μl (20 μl in each tibia) using a 30-gauge needle. There were five mice in each cohort. Flow Cytometry: Peripheral blood samples from mice were analyzed on weeks 2, 4 and 6. Bone marrow tissue samples from mice were analyzed on week 6. Peripheral blood and bone marrow samples were stained for T cell markers, (CD3), myeloid markers (CD45, CD13, CD14) and with B-cell markers (CD19). Specific lineage markers (CD3, CD13, CD14 and CD19) were analyzed inside the human CD45+ population. All monoclonal antibodies (mAbs) were purchased from BD Biosciences Pharmingen (San Diego, CA) or eBioscience. At least 1 × 10^5 events were analyzed per conjugated MAb stain condition. Data were analyzed using CFlow.

The liver, ileum, ascending colon, and right tibia were harvested. Organs were fixed in 10% buffered formalin, embedded in paraffin, cut into 5μm-thick sections, and stained with hematoxylin and eosin for histological examination. Slides were coded without reference to transplant group or treatment and reviewed in blinded fashion by a single pathologist. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Case Western Reserve University (IACUC protocol 2015-0118).

**Histology**

An independent hematopathologist, blinded to cohort characteristics, evaluated tibial sections, one from each mouse in every cohort (for a total of 5 per cohort), for myeloid-to-erythroid ratio, cellularity, and megakaryocyte percentages.

**Statistics**

All values are expressed as the mean plus or minus standard error of the mean (± SEM). Statistical comparisons between groups were completed using Mann and Whitney test (nonparametric data).

**Results**

**IO co-transplantation of CD34+ UCB and MSC improves overall HSC engraftment and enhances CD3+ T cell and CD19+ B cell recovery**

Following irradiation, recipient mice were injected with MSC and CD34+ UCB via either the IV or IO route. At six weeks following transplantation, we assessed the degree of hematopoietic engraftment that can be traced to human CD34+ lineage by measuring cells that stained positive for human CD45 by flow cytometry. Cellular engraftment was significantly enhanced in the group receiving the IO co-transplantation of UCB and MSC as compared to IV UCB alone (34% vs. 2.9%, respectively; Figure 1 and Table 1; p < 0.001). Consistent with our hypothesis that administration of MSC improves overall UCB engraftment, we observed that any combination of UCB and MSC co-administration, irrespective of the mode of delivery of either the UCB or MSC, exhibited significantly improved HSC engraftment as compared to IV UCB injection alone. In particular, direct IO administration of UCB in the presence of either IO or IV MSC led to a trend towards
improved engraftment at 6 weeks among CD45+ lineage cells as well as CD3+, CD13+, CD14+ and CD19+ cells (Table 1).

CD19+ B cell and CD3+ T cells recovery was significantly increased (p < 0.001 and p < 0.05, respectively) in the IO UCB and MSC co-transplantation cohort compared to IV UCB only cohort (B-cell 28% vs. 2%; T-cell 3% vs. 0.1%; Figure 1 and Table 1). Both the IV UCB/IV MSC and the IO UCB/IV MSC cohorts demonstrated significant improvement in engraftment over the IV UCB control. Specifically, CD19+ B cell recovery was significantly elevated in mice that received both UCB and MSC concurrently using the same route (IO or IV) of administration (28% vs. 21%, respectively) as compared to CD19+ B cell recovery when UCS and MSC were administered via different routes (IV/IO, 4%, IO/IV, 3%, respectively).

**Direct histologic evaluation of IO injected bone marrow**

Next, we correlated our flow cytometric analyses of hematopoietic recovery with direct cellularity assessment of the injected mouse bone marrow compartments (Figure 2). An analysis of the marrow cellularity by an un-biased hematopathologist revealed a myeloid-to-erythroid ratio of roughly 10:1 in all the mouse cohorts (Table 2). Interestingly, although statistically non-significant, the number of megakaryocyte per high-powered field was highest in the cohort with IV co-infused UCB and MSC. The overall bone marrow cellularity varied widely between cohort samples, and no significant differences were detected among cohorts (Table 2). These morphological data did not directly correlate with the numerical analysis of hematopoietic and immune reconstitution within the bone marrow samples by the more quantitative flow cytometry analysis.

**Discussion**

In our current study, we demonstrated that IO co-transplantation of CD34-selected UCB and MSCs improved human hematopoietic cell engraftment over UCB controls administered IV. Interestingly, we also observed a predominance of early B-cell engraftment (CD19) within the bone marrow. Our observation is in agreement with previous published reports of human UCB engraftment in NOD/SCID mice [21,22]. It is not surprising that co-localizing MSCs and UCB within the bone improves engraftment, as MSCs support hematopoiesis through a number of mechanisms within the bone marrow niche. These mechanisms include cytokine support [16,17], especially within the perivascular space within the marrow where MSCs secrete CXCL12 and stem cell factor [18]. Furthermore, the injected MSC may have a role in replacing damaged or ineffective marrow resident MSCs. Our data demonstrating that IO co-administration of UCB and MSC resulted in a significant increase in both the CD19+ B-cell and CD3+ T-cell populations within the bone marrow suggest that MSCs, especially when directly co-infused into the bone marrow niche with UCBs, allow for a more robust immunologic re-constitution of the HSCs from UCB. Potential mechanisms by which MSC accomplish this is to act through both soluble factors, such as cytokines and growth factors, as well as via direct cell-cell contact with HSCs and cells of the bone marrow niche [23,24]. Direct contact of HSC by MSC in ex vivo expansion studies have demonstrated an increase in early lymphoid progenitors production [25,26]. Indeed, the importance of MSC support
and interaction with the hematopoietic stem cell may be exemplified by the similar engraftment rate of the IO UCB cohort compared to the IV UCB cohort. The specific interaction between MSC and UCB in the bone marrow is not addressed in our study, and future investigations in this area may yield further scientific and mechanistic insights.

We did not observe a significant difference in CD45⁺, CD3⁺, CD13⁺, CD14⁺ or CD19⁺ cells in the peripheral blood among any of our cohorts at week 3 and week 6. However, human bone marrow engraftment in the absence of peripheral engraftment is considered an adequate surrogate marker in mice models [22].

Interestingly, a detailed histological analysis of the injected bone marrow did not demonstrate any differences in overall cellularity, megakaryocytic: erythrocytic (M:E) ratio, or the percentages of megakaryocytes among cohorts. This may be due to autologous recovery of murine bone marrow cells, which accompanied human UCB HSC engraftment. It is noteworthy that in the histologic evaluation of the IO MSC and IO UCB cohort, we observed an abundance of stromal tissue within the bone marrow microenvironment (Figure 2).

Overall, our results support and form the scientific basis for a new method of UCB transplantation that can be translated into clinical practice. UCB represents an important graft source for roughly one third of potential SCT patients who do not have a HLA matched related or unrelated donor [27,28]. However, UCB as a HSC source has its limitations, including lower cells dose resulting in slow or poor engraftment [1,29,30]. Various methods to optimize clinical UCB engraftment have been tried including ex-vivo expansion of UCB, intra-osseous transplantation of UCB, and intravenous co-transplantation of UCB and MSCs [12,20,31]. In addition, it has been demonstrated in patients that direct IO transplantation of a single UCB unit is safe, effective, and well tolerated following non-myeloablative conditioning preparatory regimen [31,32]. As a direct translation of our study presented here, we have now opened a clinical trial utilizing direct IO co-infusion of UCB and allogeneic MSC at the Seidman Cancer Center of the University Hospitals Case Medical Center (NCT02181478).

Acknowledgments

We thank Jane Reese and the Cellular Therapy Integrated Service of the National Center for Regenerative Medicine at Case Western Reserve University for their assistance.

Funding: This study was supported by NIH K12CA076917 Paul Calabresi Career Development Award for Clinical Oncology (K12); Clinical Oncology Research Career Development Program (L.M.III), Theresia G. & Stuart F. Kline Family Foundation in Pediatric Oncology (A.Y.H.), and the Stem Cell Transplant Program at the Seidman Cancer Center at University Hospitals Case Medical Center.

References

1. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004; 351:2276–2285. [PubMed: 15564544]

2. Hogan CJ, Shpall EJ, McNulty O, McNiece I, Dick JE, et al. Engraftment and development of human CD34(+)–enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood. 1997; 90:85–96. [PubMed: 9207442]

Hematol Med Oncol. Author manuscript; available in PMC 2016 November 21.
3. Li ZY, Wang CQ, Lu G, Pan XY, Xu KL. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model. Cell Biochem Biophys. 2014; 70:115–122. [PubMed: 24696072]

4. Piacibello W, Sanavio F, Severino A, Danè A, Gamaitoni L, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood. 1999; 93:3736–3749. [PubMed: 10339480]

5. Wang J, Kimura T, Asada R, Harada S, Yokota S, et al. SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood. 2003; 101:2924–2931. [PubMed: 12480697]

6. Cui J, Wahl RL, Shen T. Bone marrow cell trafficking following intravenous administration. Br J Haematol. 1999; 107:895–902. [PubMed: 10606901]

7. Van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood. 1999; 94:3055–3061. [PubMed: 10556189]

8. Zhong JF, Zhan Y, Anderson WF, Zhao Y. Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation. Blood. 2002; 100:3521–3526. [PubMed: 12480697]

9. Castello S, Podesta M, Menditto VG. Intra-bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency. Exp Hematol. 2004; 32:782–787. [PubMed: 15308330]

10. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med. 2003; 9:959–963. [PubMed: 12796774]

11. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 37:359–366. [PubMed: 16400333]

12. De Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012; 367:2305–2315. [PubMed: 23234514]

13. Verfaillie CM. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood. 1992; 79:2821–2826. [PubMed: 13751113]

14. Choudhury C, Sparks R. Role of the microenvironment on hematopoiesis. II. Regulation of cell kinetics in vitro during granulopoiesis and megakaryocytopenies. The Journal of Laboratory and Clinical Medicine. 1989; 114:382–388. [PubMed: 2794749]

15. Carrancio S, Blanco B, Romo C, Munition S, Lopez-Holgado N, et al. Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment. PLoS One. 2011; 6:e26241. [PubMed: 22028841]

16. Cheng L, Qasba P, Vanguri P, Thiede MA. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol. 2000; 184:58–69. [PubMed: 10825234]

17. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology. 1998 Jul; 176(1):57–66. 1998. [PubMed: 9618145]

18. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466:829–834. [PubMed: 20703299]

19. Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004; 103:3313–3319. [PubMed: 14715641]

20. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of

Hematol Med Oncol. Author manuscript; available in PMC 2016 November 21.
unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009; 43:447–454. [PubMed: 18955980]

21. Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, et al. Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant. 2013; 22:1171–1183. [PubMed: 23031585]

22. Ueda T, Yoshino H, Kobayashi K, Kawahata M, Ebihara Y, et al. Hematopoietic repopulating ability of cord blood CD34(+) cells in NOD/Shi-scid mice. Stem Cells. 2000; 18:204–213. [PubMed: 10840074]

23. Oostendorp RA, Robin C, Steinhoff C, Marz S, Bräuer R, et al. Long-term maintenance of hematopoietic stem cells does not require contact with embryo-derived stromal cells in cocultures. Stem Cells. 2005; 23:842–851. [PubMed: 15917480]

24. Wagner W, Wein F, Roderburg C. Adhesion of hematopoietic progenitor cells to human mesenchymal stem cells as a model for cell-cell interaction. Exp Hematol. 2007; 35:314–325. [PubMed: 17258080]

25. Da Silva CL, Goncalves R, dos Santos F, Andrade PZ, Almeida-Porada G, et al. Dynamic cell-cell interactions between cord blood haematopoietic progenitors and the cellular niche are essential for the expansion of CD34+, CD34+CD38- and early lymphoid CD7+ cells. J Tissue Eng Regen Med. 2010; 4:149–158. [PubMed: 19937912]

26. Frias AM, Porada CD, Crapnell KB, Cabral JM, Zanjani ED, et al. Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. Exp Hematol. 2008; 36:61–68. [PubMed: 18155552]

27. Karanes C, Nelson GO, Chitphakdithai P. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biology of Blood and Marrow Transplantation. 2008; 14:8–15. [PubMed: 18721775]

28. Confer D, Robinett P. The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2008; 42(1):S3–3S5. [PubMed: 18724295]

29. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001; 344:1815–1822. [PubMed: 11407342]

30. Cornetta K, Laughlin M, Carter S. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant. 2005; 11:149–160. [PubMed: 15682076]

31. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008; 9:831–839. [PubMed: 18693069]

32. Rocha V, Labopin M, Ruggeri A. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation. 2013; 95:1284–1291. [PubMed: 23507699]

**Abbreviations and symbols**

| Abbreviation | Definition |
|--------------|------------|
| MSC          | Human mesenchymal stromal cells |
| HSC          | Hematopoietic stem cells |
| UCB          | Umbilical cord blood |
| IO           | Intra-osseous |
| IV           | Intravenous |
| NSG          | Non-obese diabetic severe combined immunodeficiency- IL2Rgamma null |
| SCT          | Stem cell transplant |
mAbs  Monoclonal antibodies
PBS  Phosphate Buffered Saline
HAS  Human Serum Albumin
IACUC  Institutional Animal Care and Use Committee
SEM  Standard error of the mean
Figure 1.
Percent CD45, CD3, CD13, CD14, CD19 in the right tibia bone marrow at 6 weeks post umbilical cord blood infusion. IV UCB = intravenous umbilical cord blood, IO UCB = intra-osseous umbilical cord blood, IV UCB + IV MSC = intravenous umbilical cord blood and mesenchymal stromal cells, IO UCB + IO MSC = intra-osseous umbilical cord blood and mesenchymal stromal cells, IV UCB + IO MSC = intravenous umbilical cord blood and intra-osseous mesenchymal stromal cells, IO UCB + IV MSC = intra-osseous umbilical cord blood and INTRAVENOUS mesenchymal stromal cells (* = p < 0.05; ** = p < 0.001). p-values as compared to the intravenous umbilical cord blood group.
Figure 2.
Histology of right tibia bone marrow from murine cohorts. A = intravenous (IV) umbilical cord blood (UCB), B = IV UCB and IV Mesenchymal Stromal Cells (MSC), C = intra-osseous (IO) UCB, D = IO UCB and IO MSC, F = IO UCB and IV MSC, and F = IV UCB and IO MSC.
Table 1

Summary of the percent CD45, CD3, CD13, CD14, CD19 in the right tibia bone marrow at 6 weeks post umbilical cord blood infusion.

|        | IV UCB | IO UCB | IV UCB + IO MSC | IV UCB + IV MSC | IO UCB + IV MSC | IO UCB + IO MSC |
|--------|--------|--------|-----------------|-----------------|-----------------|-----------------|
| CD45   | 2.9%   | 2.5%   | 7% (p > 0.05)   | 22% (p < 0.01)  | 31% (p < 0.01)  | 34% (p < 0.01)  |
| CD3    | 0.1%   | 0.2%   | 0.2% (p > 0.05) | 0.5% (p > 0.05) | 1.4% (p > 0.05) | 3% (p > 0.05)   |
| CD13   | 0.3%   | 0.7%   | 2.6% (p > 0.05) | 0.3% (p > 0.05) | 4.8% (p > 0.05) | 4.7% (p > 0.05) |
| CD14   | 0.4%   | 0.2%   | 0.3% (p > 0.05) | 0.5% (p > 0.05) | 0.2% (p > 0.05) | 0.9% (p > 0.05) |
| CD19   | 2.0%   | 0.9%   | 4% (p > 0.05)   | 21% (p < 0.01)  | 3% (p > 0.05)   | 28% (p < 0.01)  |

IV UCB = intravenous umbilical cord blood, IO UCB = intra-osseous umbilical cord blood, IV UCB + IV MSC = intravenous umbilical cord blood and mesenchymal stromal cells, IO UCB + IO MSC = intra-osseous umbilical cord blood and mesenchymal stromal cells, IV UCB + IO MSC = intravenous umbilical cord blood and intra-osseous mesenchymal stromal cells, IO UCB + IV MSC = intra-osseous umbilical cord blood and INTRAVENOUS mesenchymal stromal cells. p-values as compared to the intravenous umbilical cord blood group.
Table 2

Tabulation of histologic analysis from murine cohorts.

|                          | IV UCB | IO UCB | IV UCB + IO MSC | IV UCB + IV MSC | IO UCB + IO MSC |
|--------------------------|--------|--------|-----------------|-----------------|-----------------|
| Megakaryocyte per high power field | 1.2    | 1.3    | 0.9             | 2.3             | 2.2             | 0.4             |
| Myeloid–to-erythroid Ratio | 10:1   | 10:1   | 10:1            | 10:1            | 10:1            | 10:1            |
| Cellularity              | 62%    | 68%    | 82%             | 50%             | 46%             | 47%             |

IV UCB = intravenous umbilical cord blood, IO UCB = intra-osseous umbilical cord blood, IV UCB + IV MSC = intravenous umbilical cord blood and mesenchymal stromal cells, IO UCB + IO MSC = intra-osseous umbilical cord blood and mesenchymal stromal cells, IV UCB + IO MSC = intravenous umbilical cord blood and intra-osseous mesenchymal stromal cells, IO UCB + IV MSC = intra-osseous umbilical cord blood and intravenous mesenchymal stromal cells.